

SESSIONS

DAY 1 08/25/2020 - 25/08/2020

ChinaBio® Partnering Forum

August 25–27, 2020

Delivered Digitally

China Standard Time

A refresher on life sciences joint ventures

09:00 - 10:00

Partnering Bootcamp LIVE

We are seeing a growing number of life science joint ventures in China. Through the panel discussions, we will explore:

- whether this is a growing trend
- when it may make sense to pursue JV versus pure licensing
- what should be done to maximize the chance of success and what pitfalls to avoid.

Participants

Moderator: James Lu, JD - Partner, Cooley LLP

Panelist: Michael Chen, PhD - Head of Business Development, Akeso Biopharma

Panelist: Marietta Wu, PhD - Managing Director, Quan Capital

Panelist: Christina Zhang, JD - Partner, Cooley LLP

Access on-demand presentations

09:00 - 08:00

Company Presentations

We have recruited some of the most innovative biotech companies and their presentations are now available on demand.

[Access on-demand presentations](#)

Partnering: One-to-one meetings

09:00 - 08:55

Partnering: One-to-one meetings

One-to-one meetings will be available to schedule online throughout the duration of the digital event.

Key IPO considerations for life sciences companies

10:00 - 11:00

Partnering Bootcamp LIVE

Life sciences IPOs have been extremely hot in the past two years, despite the pandemic and trade wars. If you are thinking about an IPO, what is the best timing? Should you choose NASDAQ or the Hong Kong Stock Exchange? A panel of experienced IPO advisors will explain the key issues every life sciences company must consider when planning an IPO.

Participants

Panelist: Will Cai, JD - Partner and Head of Asia Capital Markets, Cooley LLP

Panelist: Jun Wu - Managing Director, Head Asia Healthcare and China Investment Banking, Jefferies

Panelist: Michael Yu - Partner, Cooley LLP

Live Networking Reception Hosted by ATLATL

19:00 - 21:00

Networking

Local Shanghai delegates are invited to attend the networking reception at the ATLATL Research Center. ATLATL Research Center, Zhangjiang Hi-Tech Park, 1077 Zhangheng Road, Pudong New District, Shanghai

Forging ahead in unprecedented times: The path forward

21:00 - 22:00

Opening Keynote & Plenary LIVE

2020 has brought more challenges than ever anticipated but the life sciences industry is paving the path forward by creating new opportunities for the development of vaccines, diagnostics and therapeutics. Executives from leading MNCs in China share their strategies in overcoming obstacles and becoming more efficient, focused and successful.

Participants

Moderator: Greg B. Scott - Founder and Chairman, ChinaBio® Group

Panelist: Betty Huang - Head, Business Development and Licensing, China/APAC Region, Bayer HealthCare

Panelist: Matthieu Merlin - Head of BD&L C&EM/JPAC, Sanofi

Panelist: Sophie Sun, MBA - Managing Director, Merck China Innovation Hub; VP, Merck Strategy and Transformation China, Merck

Panelist: Yingjie Wu, PhD - Head, Roche Pharma Partnering China

Panelist: Dan Wang, MD, MBA - Head, Asia Pacific, Johnson & Johnson Innovation

Panelist: Ying Yang, PhD - VP, Worldwide Business Development Asia Lead, Pfizer Investment Co., Ltd.

SCHEDULE

DAY 1 08/25/2020 - 25/08/2020

ChinaBio® Partnering Forum

August 25–27, 2020

Delivered Digitally
China Standard Time

TIME	COMPANY PRESENTATIONS	NETWORKING	OPENING KEYNOTE & PLENARY LIVE	PARTNERING BOOTCAMP LIVE	PARTNERING: ONE-TO-ONE MEETINGS
09:00	09:00 - Access on-demand presentations			09:00 - A refresher on life sciences joint ventures	09:00 - Partnering: One-to-one meetings
10:00				10:00 - Key IPO considerations for life sciences companies	
11:00					
12:00					
13:00					
14:00					
15:00					
16:00					
17:00					
18:00					
19:00		19:00 - Live Networking Reception Hosted by ATLATL			
20:00					
21:00			21:00 - Forging ahead in unprecedented times: The path forward		

SESSIONS

DAY 2 - 08/26/2020 - 26/08/2020

ChinaBio® Partnering Forum

August 25–27, 2020
Delivered Digitally
China Standard Time

Innovation in China: Rapid evolution

08:00 - 09:00
Panels

China has been rapidly catching up with global innovation, and the current crisis has had significant impact, both positive and negative. How are companies in China using innovation to address unmet medical needs, whether chronic diseases, genetic disorders, or viruses? How are cutting edge technologies making significant advances in healthcare? Leaders from innovative companies highlight their progress.

Participants

Moderator: Yuwen Liu - Founding Partner, BOHE Angel Fund

Panelist: Jasmine Cui, PhD - Co-Founder, President and CEO, InnoCare

Panelist: Konstantin Poukalov - Managing Director, Strategy, Perceptive Advisors

Panelist: Dajun Yang, MD, PhD - Chairman and CEO, Ascentage Pharma

Panelist: Frank Zhang, PhD - Chairman, Legend Bio

Panelist: Xiaotong Zhu - President, Luoxin Pharmaceutical (Shanghai) Co., Ltd

Access on-demand presentations

08:00 - 15:00
Company Presentations

We have recruited some of the most innovative biotech companies and their presentations are now available on demand.

[Access on-demand presentations](#)

Partnering: One-to-one meetings

08:00 - 07:00
Partnering: One-to-one meetings

One-to-one meetings will be available to schedule online throughout the duration of the digital event.

Live Networking Hours/ Virtual Breakouts

08:00 - 09:00
Networking

Navigate through COVID-19 turmoil and safeguard cross-border life sciences transactions

09:00 - 10:00
Panels

Amid the COVID-19 pandemic that is reshaping the world and in particular the healthcare industry, life sciences investments in 2020 have showed an upbeat picture as funding to healthcare companies was up 4% quarter-over-quarter in Q1 2020, reaching an amount of US\$14.6 billion. While the healthcare sector starts to emerge from the crisis and the outbreak is leading to policy changes such as the liberalization of telemedicine services, the newly effective CFIOUS implementation regulations have expanded its jurisdiction and more FDI screening rules will soon come to effect across Europe, all presenting unique challenges to cross-border transactions. Finding ways to navigate through the turmoil has become a critical subject to global investors.

Participants

Moderator: Chuan Sun, JD, PhD - Partner, Morrison & Foerster

Panelist: Joseph Benkert, MPP - Senior Advisor, Morrison & Foerster

Panelist: Bethany Hills, JD, MPH - Partner, Morrison & Foerster

Panelist: Wolfgang Schöning, JD, LL.M. - Partner, Morrison & Foerster

SCHEDULE

DAY 2 - 08/26/2020 - 26/08/2020

ChinaBio® Partnering Forum

August 25–27, 2020

Delivered Digitally

China Standard Time

TIME	COMPANY PRESENTATIONS	NETWORKING	PANELS	PARTNERING: ONE-TO-ONE MEETINGS
08:00	08:00 - Access on-demand presentations	08:00 - Live Networking Hours/ Virtual Break-outs	08:00 - Innovation in China: Rapid evolution	08:00 - Partnering: One-to-one meetings
09:00			09:00 - Navigate through COVID-19 turmoil and safeguard cross-border life sciences transactions	

SESSIONS

DAY 3 - 08/27/2020 - 27/08/2020

ChinaBio® Partnering Forum

August 25–27, 2020
Delivered Digitally
China Standard Time

Access on-demand presentations

08:00 - 07:00

Company Presentations

We have recruited some of the most innovative biotech companies and their presentations are now available on demand.

[Access on-demand presentations](#)

Partnering: One-to-one meetings

08:00 - 00:00

Partnering: One-to-one meetings

One-to-one meetings will be available to schedule online throughout the duration of the digital event.

The road to commercialization

20:00 - 21:00

Panels

The journey to develop new treatments and cures is challenging but with the right partners in place, obstacles can be avoided. Industry leaders in the development of biologics, cell and gene therapies, and other advanced therapies highlight the importance of working with partners to accelerate commercialization.

Participants

Moderator: Brian Yang - Senior Editor, Informa Pharma Intelligence

Panelist: Hui Feng, PhD - COO, Junshi Biosciences

Panelist: Jeff Li - General Manager China, Lonza Pharma Biotech & Nutrition

Panelist: Mai-Jing Liao, MD - CBO, Harbour BioMed

Panelist: Marietta Wu, PhD - Managing Director, Quan Capital

China Investment: Sunny days or gray skies ahead?

21:00 - 22:00

Panels

The outlook is positive for both inbound and outbound investment opportunities in China, with fundraising on track for another record year. Funding is still readily available for both domestic and US/EU/APAC companies with the right combination of science, people and strategy. Leading VCs provide insights on how to attract capital, when and where to seek investments, and how you can best position your company for success.

Participants

Moderator: Greg B. Scott - Founder and Chairman, ChinaBio® Group

Panelist: Nisa Leung - Managing Partner, Qiming Ventures

Panelist: Yi Shi - Managing Partner, Lilly Asia Ventures

Panelist: Stella Xu - Managing Director, Quan Capital

A herd of biotech unicorns

22:00 - 23:00

Panels

Amidst a global pandemic, capital markets remain healthy for innovative life science companies in China. To date, 2020 is on track to set new records for the number and size of biotech IPOs. In 1H 2020, 30 IPOs have raised over \$5.5B on the Shanghai STAR, Hong Kong and NASDAQ exchanges, creating seven new unicorns in the process. Leading biotechs that have recently listed share their strategies in determining when and where to file their IPOs.

Participants

Moderator: Debra Yu, MD - President and CBO, LianBio

Panelist: Trency Gu - Managing Director, Sequoia China

Panelist: Bin Li - Founding Partner and CEO, Lake Bleu Capital

Panelist: Xuefeng Yu, PhD - Chairman, CEO, General Manager, Co-Founder, CanSino Biologics

Panelist: Jielun Zhu - CFA, CFO, Executive Director, I-Mab Biopharma Co., Ltd

SCHEDULE

DAY 3 - 08/27/2020 - 27/08/2020

ChinaBio® Partnering Forum

August 25–27, 2020

Delivered Digitally

China Standard Time

TIME	COMPANY PRESENTATIONS	PANELS	PARTNERING: ONE-TO-ONE MEETINGS
08:00	08:00 - Access on-demand presentations		08:00 - Partnering: One-to-one meetings
09:00			
10:00			
11:00			
12:00			
13:00			
14:00			
15:00			
16:00			
17:00			
18:00			
19:00			
20:00		20:00 - The road to commercialization	
21:00		21:00 - China Investment: Sunny days or gray skies ahead?	
22:00		22:00 - A herd of biotech unicorns	